This concept suggests FNDC5/irisin may have an important role as a protective myo‐adipokine opposing the development of insulin resistance in the stages of prediabetes and provides further support for the use of FNDC5/irisin as a potential therapeutic treatment for obesity and related metabolic disorders. This evidence concerns the gene FNDC5 and Other metabolic disease.